Trevi Therapeutics (NASDAQ:TRVI) Earns Buy Rating from Analysts at HC Wainwright

HC Wainwright started coverage on shares of Trevi Therapeutics (NASDAQ:TRVI – Free Report) in a report published on Friday, Marketbeat reports. The brokerage issued a buy rating and a $6.00 target price on the stock. TRVI has been the subject of several other research reports. EF Hutton Acquisition Co. I raised shares of Trevi Therapeutics […]

Leave a Reply

Your email address will not be published.

Previous post Firsthand Technology Value Fund (NASDAQ:SVVC) Coverage Initiated by Analysts at StockNews.com
Next post Aehr Test Systems (NASDAQ:AEHR) Sees Significant Increase in Short Interest